NBW Capital LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 65,133 shares of the biotechnology company’s stock, valued at approximately $1,980,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC bought a new stake in Exelixis in the third quarter valued at $120,000. Sigma Planning Corp bought a new stake in Exelixis in the fourth quarter valued at $208,000. American International Group Inc. bought a new stake in Exelixis in the fourth quarter valued at $208,000. Klingenstein Fields & Co. LLC bought a new stake in Exelixis in the fourth quarter valued at $213,000. Finally, Globeflex Capital L P bought a new stake in Exelixis in the fourth quarter valued at $246,000. 80.55% of the stock is currently owned by institutional investors.
Several research firms recently weighed in on EXEL. Cann reiterated a “buy” rating and issued a $40.00 price target on shares of Exelixis in a report on Thursday. ValuEngine cut shares of Exelixis from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. BidaskClub cut shares of Exelixis from a “buy” rating to a “hold” rating in a report on Thursday, March 1st. Stifel Nicolaus lifted their price target on shares of Exelixis from $29.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, February 27th. Finally, Oppenheimer upgraded shares of Exelixis from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $34.10.
Shares of Exelixis, Inc. (NASDAQ EXEL) opened at $24.53 on Monday. The company has a market cap of $7,268.42, a price-to-earnings ratio of 48.10, a PEG ratio of 1.29 and a beta of 1.96. Exelixis, Inc. has a fifty-two week low of $18.03 and a fifty-two week high of $32.50.
Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Monday, February 26th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.12. The company had revenue of $120.10 million for the quarter, compared to analysts’ expectations of $120.25 million. Exelixis had a net margin of 34.08% and a return on equity of 81.05%. Exelixis’s revenue was up 54.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.12 EPS. equities analysts forecast that Exelixis, Inc. will post 0.59 earnings per share for the current year.
WARNING: “NBW Capital LLC Takes Position in Exelixis, Inc. (EXEL)” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/03/12/nbw-capital-llc-takes-position-in-exelixis-inc-exel.html.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.